Literature DB >> 12767980

Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants.

Sameer Parekh1, Fabien Zoulim, Sang Hoon Ahn, Adrienne Tsai, Jisu Li, Shigenobu Kawai, Nasser Khan, Christian Trépo, Jack Wands, Shuping Tong.   

Abstract

The core promoter mutants of hepatitis B virus (HBV) emerge as the dominant viral population at the late HBeAg and the anti-HBe stages of HBV infection, with the A1762T/G1764A substitutions as the hotspot mutations. The double core promoter mutations were found by many investigators to moderately enhance viral genome replication and reduce hepatitis B e antigen (HBeAg) expression. A much higher replication capacity was reported for a naturally occurring core promoter mutant implicated in the outbreak of fulminant hepatitis, which was caused by the neighboring C1766T/T1768A mutations instead. To systemically study the biological properties of naturally occurring core promoter mutants, we amplified full-length HBV genomes by PCR from sera of HBeAg(+) individuals infected with genotype A. All 12 HBV genomes derived from highly viremic sera (5 x 10(9) to 5.7 x 10(9) copies of viral genome/ml) harbored wild-type core promoter sequence, whereas 37 of 43 clones from low-viremia samples (0.2 x 10(7) to 4.6 x 10(7) copies/ml) were core promoter mutants. Of the 11 wild-type genomes and 14 core promoter mutants analyzed by transfection experiments in human hepatoma cell lines, 6 core promoter mutants but none of the wild-type genomes replicated at high levels. All had 1762/1764 mutations and an additional substitution at position 1753 (T to C), at position 1766 (C to T), or both. Moreover, these HBV clones varied greatly in their ability to secrete enveloped viral particles irrespective of the presence of core promoter mutations. High-replication clones with 1762/1764/1766 or 1753/1762/1764/1766 mutations expressed very low levels of HBeAg, whereas high-replication clones with 1753/1762/1764 triple mutations expressed high levels of HBeAg. Experiments with site-directed mutants revealed that both 1762/1764/1766 and 1753/1762/1764/1766 mutations conferred significantly higher viral replication and lower HBeAg expression than 1762/1764 mutations alone, whereas the 1753/1762/1764 triple mutant displayed only mild reduction in HBeAg expression similar to the 1762/1764 mutant. Thus, core promoter mutations other than those at positions 1762 and 1764 can have major impact on viral DNA replication and HBeAg expression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12767980      PMCID: PMC156182          DOI: 10.1128/jvi.77.12.6601-6612.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

Review 1.  Clinical significance of hepatitis B virus genotypes.

Authors:  Chi-Jen Chu; Anna S F Lok
Journal:  Hepatology       Date:  2002-05       Impact factor: 17.425

2.  Critical roles of nuclear receptor response elements in replication of hepatitis B virus.

Authors:  X Yu; J E Mertz
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

3.  Replication of the genome of a hepatitis B--like virus by reverse transcription of an RNA intermediate.

Authors:  J Summers; W S Mason
Journal:  Cell       Date:  1982-06       Impact factor: 41.582

4.  No significant correlation exists between core promoter mutations, viral replication, and liver damage in chronic hepatitis B infection.

Authors:  Y K Chun; J Y Kim; H J Woo; S M Oh; I Kang; J Ha; S S Kim
Journal:  Hepatology       Date:  2000-11       Impact factor: 17.425

5.  Expression of the precore region of an avian hepatitis B virus is not required for viral replication.

Authors:  C Chang; G Enders; R Sprengel; N Peters; H E Varmus; D Ganem
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

6.  A dominant hepatitis B virus population defective in virus secretion because of several S-gene mutations from a patient with fulminant hepatitis.

Authors:  T Kalinina; A Riu; L Fischer; H Will; M Sterneck
Journal:  Hepatology       Date:  2001-08       Impact factor: 17.425

7.  Replication of the wild type and a natural hepatitis B virus nucleocapsid promoter variant is differentially regulated by nuclear hormone receptors in cell culture.

Authors:  H Tang; A K Raney; A McLachlan
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

8.  Identification and expression of glycine decarboxylase (p120) as a duck hepatitis B virus pre-S envelope-binding protein.

Authors:  J Li; S Tong; J R Wands
Journal:  J Biol Chem       Date:  1999-09-24       Impact factor: 5.157

9.  Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers.

Authors:  Jia-Horng Kao; Pei-Jer Chen; Ming-Yang Lai; Ding-Shinn Chen
Journal:  Gastroenterology       Date:  2003-02       Impact factor: 22.682

10.  Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease.

Authors:  Hajime Sumi; Osamu Yokosuka; Naohiko Seki; Makoto Arai; Fumio Imazeki; Tomoko Kurihara; Tatsuo Kanda; Kenichi Fukai; Masaki Kato; Hiromitsu Saisho
Journal:  Hepatology       Date:  2003-01       Impact factor: 17.425

View more
  93 in total

1.  Differential regulation of hepatitis B virus core protein expression and genome replication by a small upstream open reading frame and naturally occurring mutations in the precore region.

Authors:  Li Zong; Yanli Qin; Haodi Jia; Lei Ye; Yongxiang Wang; Jiming Zhang; Jack R Wands; Shuping Tong; Jisu Li
Journal:  Virology       Date:  2017-03-03       Impact factor: 3.616

2.  Distinguishing reversible from irreversible virus capsid assembly.

Authors:  Adam Zlotnick
Journal:  J Mol Biol       Date:  2006-11-11       Impact factor: 5.469

3.  Improved method for rapid and efficient determination of genome replication and protein expression of clinical hepatitis B virus isolates.

Authors:  Yanli Qin; Jiming Zhang; Tamako Garcia; Kiyoaki Ito; Danielle Gutelius; Jisu Li; Jack Wands; Shuping Tong
Journal:  J Clin Microbiol       Date:  2011-02-02       Impact factor: 5.948

4.  Point mutations upstream of hepatitis B virus core gene affect DNA replication at the step of core protein expression.

Authors:  Michael Guarnieri; Kyun-Hwan Kim; Genie Bang; Jisu Li; Yonghong Zhou; Xiaoli Tang; Jack Wands; Shuping Tong
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

5.  Temporal acquisition of sequential mutations in the enhancer II and basal core promoter of HBV in individuals at high risk for hepatocellular carcinoma.

Authors:  Xin Bai; Yu Zhu; Yan Jin; Xia Guo; Gengsun Qian; Taoyang Chen; Jing Zhang; Jinbing Wang; John D Groopman; Jianren Gu; Hong Tu
Journal:  Carcinogenesis       Date:  2010-09-28       Impact factor: 4.944

Review 6.  Pathogenesis of hepatitis B virus infection.

Authors:  Thomas F Baumert; Robert Thimme; Fritz von Weizsäcker
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

7.  Critical role of the 36-nucleotide insertion in hepatitis B virus genotype G in core protein expression, genome replication, and virion secretion.

Authors:  Ke Li; Fabien Zoulim; Christian Pichoud; Karen Kwei; Stéphanie Villet; Jack Wands; Jisu Li; Shuping Tong
Journal:  J Virol       Date:  2007-06-13       Impact factor: 5.103

Review 8.  Genotypes and viral variants in chronic hepatitis B: A review of epidemiology and clinical relevance.

Authors:  Catherine Mn Croagh; Paul V Desmond; Sally J Bell
Journal:  World J Hepatol       Date:  2015-03-27

9.  Reactive Oxygen Species-Mediated c-Jun NH2-Terminal Kinase Activation Contributes to Hepatitis B Virus X Protein-Induced Autophagy via Regulation of the Beclin-1/Bcl-2 Interaction.

Authors:  Linmao Zhong; Wangqin Shu; Wangbin Dai; Bo Gao; Sidong Xiong
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

10.  Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis.

Authors:  Shijian Liu; Hongwei Zhang; Chunying Gu; Jianhua Yin; Yongchao He; Jiaxin Xie; Guangwen Cao
Journal:  J Natl Cancer Inst       Date:  2009-07-02       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.